Replies to post #136217 on PharmaCyte Biotech Inc (PMCB)

[livendi]

but things have not gone well bro,an ind that took 4 yrs to submit and was changed from a phase 3 to a 2 and fda still couldnt give us the go ahead,i agree with old musky,the problems with ind are the ind itself,to say fda just wants more info about this tech is lunacy,the looked at it and right away there were problems which is why the huge inside dump came at submission which didnt allow the pps to rise,these are facts are they not and we are at subpenny,cmon now

[$Pistol Pete$]

More hype with this 20 years old technology and no one interested it. They only used it to promote and dump shares

[thenewmixer]

this technology is worth less than a penny

[A2Z]

I’m sorry you a longs ways off if that ever happens. Depends on the number of authorize shares put back on that will be sold on the retail market. No way he can sell at discount. No one wants them. No money to be made.

Face it... your genius has ruined this company for the investor.

Hopefully it will benefit the PC patient if they can get things worked out.

I’m a seller at 6 cents. That’s my big kaboom. Then I hope it booms on up for you all

As long as you have your current genius in its houng nowhere in pps

[$Pistol Pete$]

New COO=Dilution + Reverse Split

[DragonBear]

No hype...if all goes well-it won't

If the 1980s Ifosfamide was some sort of miracle drug, where a little dab will do ya locally... then someone would've figured out how to deliver the action form locally, via ADC. And it would've been done with first line patients.

The best case scenario is the Kenny Wonder Treatment lowers the metastatic tumor load enough for to act as a palliative treatment. The patient feels better for 3 months, and then dies. With no proof CIABs are required. Such a niche treatment justifies a PPS of 0.007. All of the SH dreams of $1-$3 are unrealistic.

if a suitor wants to dabble in diabetes and mj...

There will be no suitor willing to pay $2.4B+ or $7.2B+ for CIABs, where they are off patent. In fact there will be no suitor period. The reader is invited to research recent acquisitions made, and the pipelines the acquirer obtained.

Also the PMCB scam angles pertaining to diabetes and mj are a joke.